US 12,465,595 B2
Cystic fibrosis transmembrane conductance regulator (CFTR) modulators, pharmaceutical compositions, and uses thereof
Eric Sorscher, Atlanta, GA (US); Haian Fu, Decatur, GA (US); Huw Davies, Suwanee, GA (US); Jeong Hong, Decatur, GA (US); Yuhong Du, Atlanta, GA (US); Andras Rab, Atlanta, GA (US); Candela Manfredi, Atlanta, GA (US); Xun Yang, Atlanta, GA (US); and Zhi Ren, Atlanta, GA (US)
Assigned to Emory University, Atlanta, GA (US); and Children's Healthcare of Atlanta, Inc., Atlanta, GA (US)
Appl. No. 18/018,997
Filed by Emory University, Atlanta, GA (US); and Children's Healthcare of Atlanta, Inc., Atlanta, GA (US)
PCT Filed Jul. 30, 2021, PCT No. PCT/US2021/043956
§ 371(c)(1), (2) Date Jan. 31, 2023,
PCT Pub. No. WO2022/026863, PCT Pub. Date Feb. 3, 2022.
Claims priority of provisional application 63/059,796, filed on Jul. 31, 2020.
Prior Publication US 2023/0293498 A1, Sep. 21, 2023
Int. Cl. A61K 31/427 (2006.01); A61K 31/4155 (2006.01); A61K 31/433 (2006.01)
CPC A61K 31/427 (2013.01) [A61K 31/4155 (2013.01); A61K 31/433 (2013.01)] 7 Claims
 
1. A compound that is 3-(2-bromo-5-methoxyphenyl)-6-isopropyl-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazine or a salt thereof.